| Today's Big NewsOct 25, 2022 |
|
A GPS to your next blockbuster drug - Design molecules towards your desired properties through AI+Biophysics. Learn more. 
|
|
| By Fraiser Kansteiner On the quest to simplify its operations in a post-Haleon world, GSK is “bringing together our medicines and vaccines manufacturing networks, and equivalent commercial operations, in one place,” a company spokesperson said. At the same time, 25-year veteran Roger Connor is departing his post as GSK’s president of vaccines and global health. |
|
|
|
By Max Bayer In less than a week, Ipsen's rare genetic disorder drug was set to go be reviewed by FDA's independent expert panel, but that timeline is now off. The FDA has requested additional information on clinical trial data for the med, palovarotene, delaying the meeting of the Endocrinologic and Metabolic Drugs Advisory Committee has been postponed. |
By Andrea Park Artificial intelligence is often seen as a “black box,” a scary concept that becomes even more so as the technology becomes increasingly embedded in the healthcare industry. |
By Annie Burky CommonSpirit Health is now classifying the cybersecurity incident still crippling IT systems over two weeks later as a ransomware attack. Cyber experts, including those from the American Hospital Association and the Healthcare Information and Management Systems Society, assess what is known about the recent cyber breach of CommonSpirit Health, what hospitals can do to prepare and how the government can play offense. |
By Fraiser Kansteiner With their forces—and cash—combined, venture capital outfit Eclipse and Mayo Clinic have teamed up to provide seed funding for new CDMO Nucleus RadioPharma. The company is on a mission to boost radiopharmaceutical access by cranking out new technologies to modernize development, production and supply of the promising cancer meds. |
By Max Bayer Biogen may still be basking in the positive phase 3 data of its Eisai-partnered Alzheimer’s drug lecanemab, but the big pharma's CEO has remained vague on exactly what role his company will play in the therapy's commercialization. |
By Andrea Park Verily is on the up-and-up—as in, re-upping a team-up with the Crohn’s and Colitis Foundation to help spur research into inflammatory bowel disease forward. |
By Paige Minemyer Centene brought in $738 million in profit for the third quarter, surpassing Wall Street analysts' predictions. |
By Angus Liu Novartis’ gene therapy Zolgensma ranks among six drugs that the Swiss pharma counts as its major growth drivers with multibillion-dollar peak sales potential. But the drug was missing from a list of the company's top performers in the third quarter. |
By Nick Paul Taylor GSK has axed its NY-ESO-1 T-cell receptor pact with Lyell Immunopharma, with the Big Pharma transferring the program to Adaptimmune. It means that months after stopping enrollment in a study of its first-generation NY-ESO-1 candidate, GSK has walked away from a $1 billion-plus pact with Lyell that could have delivered enhanced successors. |
By Conor Hale The company’s PromethION 2 Solo is described as about the size of a large book and can deliver high-yield sequencing at an affordable rate. |
By Heather Landi 23andMe is focused on using Lemonaid Health's virtual care and online pharmacy capabilities to build out genetically-driven telehealth and pharmacogenomic services. |
By Gabrielle Masson Diffusion Pharmaceuticals is evaluating its options amid the prolonged bear market, including partnerships, licensing deals, divestiture for some of its tech or selling off the whole biotech. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we talk about our special report on the top 10 vaccine company rankings. We also report the news on Pfizer's kickback lawsuit, OTC hearing aids and more. |
|
|---|
|
|
|
Tuesday, November 15, 2022 | 1pm ET / 10am PT In this webinar, learn how Medable is focused on improving access to clinical trials for patients, supporting the innovation of clinical trial delivery and offering greater choices for participation and engagement to patients. Register now.
|
|
eBook Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
Whitepaper Electronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
eBook Looking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
eBook In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
eBook With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
Whitepaper Read about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
Whitepaper SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
Whitepaper This paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
